HRP20160168T1 - Kristalne forme makrolida i njihova uporaba - Google Patents

Kristalne forme makrolida i njihova uporaba Download PDF

Info

Publication number
HRP20160168T1
HRP20160168T1 HRP20160168T HRP20160168T HRP20160168T1 HR P20160168 T1 HRP20160168 T1 HR P20160168T1 HR P20160168 T HRP20160168 T HR P20160168T HR P20160168 T HRP20160168 T HR P20160168T HR P20160168 T1 HRP20160168 T1 HR P20160168T1
Authority
HR
Croatia
Prior art keywords
cem
solution
water
peaks
radiation
Prior art date
Application number
HRP20160168T
Other languages
English (en)
Croatian (hr)
Inventor
David E Pereira
Original Assignee
Cempra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44673574&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20160168(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cempra Pharmaceuticals Inc filed Critical Cempra Pharmaceuticals Inc
Publication of HRP20160168T1 publication Critical patent/HRP20160168T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HRP20160168T 2010-03-22 2011-03-22 Kristalne forme makrolida i njihova uporaba HRP20160168T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31606310P 2010-03-22 2010-03-22
PCT/US2011/029424 WO2011119604A1 (en) 2010-03-22 2011-03-22 Crystalline forms of a macrolide, and uses therefor
EP11760068.4A EP2550286B1 (en) 2010-03-22 2011-03-22 Crystalline forms of a macrolide, and uses therefor

Publications (1)

Publication Number Publication Date
HRP20160168T1 true HRP20160168T1 (hr) 2016-03-25

Family

ID=44673574

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160168T HRP20160168T1 (hr) 2010-03-22 2011-03-22 Kristalne forme makrolida i njihova uporaba

Country Status (19)

Country Link
US (4) US8975386B2 (enExample)
EP (2) EP3009442B1 (enExample)
JP (4) JP5711352B2 (enExample)
KR (2) KR20180101643A (enExample)
CN (2) CN108570083A (enExample)
AU (2) AU2011232627B2 (enExample)
BR (1) BR112012023950A2 (enExample)
CA (1) CA2793884C (enExample)
DK (1) DK2550286T3 (enExample)
ES (1) ES2564097T3 (enExample)
HR (1) HRP20160168T1 (enExample)
IL (1) IL222018B (enExample)
MX (1) MX361413B (enExample)
MY (1) MY162411A (enExample)
NZ (1) NZ602544A (enExample)
PL (1) PL2550286T3 (enExample)
RU (1) RU2650883C2 (enExample)
SI (1) SI2550286T1 (enExample)
WO (1) WO2011119604A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601695B2 (en) 2003-03-10 2009-10-13 Optimer Pharmaceuticals, Inc. Antibacterial agents
EP2214484A4 (en) 2007-10-25 2013-01-02 Cempra Pharmaceuticals Inc PROCESS FOR PREPARING ANTIBACTERIAL MAKROLIDE AGENTS
CN102245195B (zh) 2008-10-24 2016-01-13 森普拉制药公司 使用含三唑的大环内酯的生物防御
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
JP5914335B2 (ja) 2009-09-10 2016-05-11 センプラ ファーマシューティカルズ，インコーポレイテッド マラリア、結核、及びｍａｃ病の治療方法
EP3009442B1 (en) 2010-03-22 2019-06-19 Cempra Pharmaceuticals, Inc. Crystalline forms of a macrolide, and uses therefor
CA2799937A1 (en) 2010-05-20 2011-11-24 Cempra Pharmaceuticals, Inc. Processes for preparing macrolides and ketolides and intermediates therefor
WO2012034058A1 (en) 2010-09-10 2012-03-15 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
CA2868262A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
HK1217665A1 (zh) 2013-03-14 2017-01-20 森普拉制药公司 用於治療呼吸道疾病的方法及其製劑
HK1218864A1 (zh) 2013-03-15 2017-03-17 森普拉制药公司 用於制备大环内酯抗菌剂的收敛方法
KR102363621B1 (ko) 2013-04-04 2022-02-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 매크롤라이드 그리고 그의 제조방법 및 용도
JP2017523975A (ja) * 2014-08-05 2017-08-24 センプラ ファーマシューティカルズ，インコーポレイテッド 経口抗菌薬粉末懸濁製剤
CN104151382B (zh) * 2014-08-08 2016-09-14 广东东阳光药业有限公司 一种固态大环内酯的晶型
CN104311611B (zh) * 2014-08-13 2017-01-18 广东东阳光药业有限公司 一种制备固态大环内酯的方法
CA2963815A1 (en) 2014-10-08 2016-04-14 President And Fellows Of Harvard College 14-membered ketolides and methods of their preparation and use
WO2016154591A1 (en) 2015-03-25 2016-09-29 President And Fellows Of Harvard College Macrolides with modified desosamine sugars and uses thereof
JP6112696B1 (ja) * 2015-10-05 2017-04-12 富山化学工業株式会社 ソリスロマイシンを含む錠剤
EP3190122A1 (en) * 2016-01-08 2017-07-12 LEK Pharmaceuticals d.d. A novel synthetic pathway towards solithromycin and purification thereof
TW201811811A (zh) * 2016-09-02 2018-04-01 森普拉製藥公司 製備氟酮內酯之方法
JP7693669B2 (ja) * 2019-12-02 2025-06-17 アリクァンタムアールエクス，インコーポレイテッド 疾患の治療のためのセスロマイシンの塩及び多形体 セスロマイシンの塩及び多形体

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4742049A (en) 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
IL114589A (en) 1990-11-21 1999-12-22 Roussel Uclaf Intermediates for the preparation of erythromycin derivatives
US5985844A (en) 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
FR2697524B1 (fr) 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2718450B1 (fr) 1994-04-08 1997-01-10 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
FR2739620B1 (fr) 1995-10-09 1997-12-19 Roussel Uclaf Nouveaux derives de la 5-0-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
FR2742757B1 (fr) 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2745290B1 (fr) 1996-02-28 1998-04-03 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
ES2242983T3 (es) 1996-09-04 2005-11-16 Abbott Laboratories Cetolidos 6-0-sustituidos que tienen una actividad antibacteriana.
HN1998000086A (es) 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
CN1259135A (zh) 1997-06-11 2000-07-05 辉瑞产品公司 9－肟红霉素衍生物
US6407074B1 (en) 1997-06-11 2002-06-18 Pfizer Inc C-4″-substituted macrolide derivatives
HN1998000159A (es) 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
IL135792A0 (en) 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
FR2777282B1 (fr) 1998-04-08 2001-04-20 Hoechst Marion Roussel Inc Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments
US6020521A (en) 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
FR2785612A1 (fr) 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2786188B1 (fr) 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
KR100317907B1 (ko) * 1998-11-24 2001-12-24 김 완 주 신규한 중간체, 이를 이용한 마크로라이드계 항생제의제조방법
ATE344269T1 (de) 1998-12-10 2006-11-15 Pfizer Prod Inc Carbamat und carbazat ketolid antibiotika
CZ20012675A3 (cs) 1999-01-27 2002-04-17 Pfizer Products Inc. Ketolidová antibiotika
CA2292359C (en) 1999-01-28 2004-09-28 Pfizer Products Inc. Novel azalides and methods of making same
CA2370743A1 (en) 1999-04-16 2000-10-26 Dennis Hlasta Ketolide antibacterials
AU775637B2 (en) 1999-04-16 2004-08-12 Kosan Biosciences, Inc. Macrolide antiinfective agents
US6420535B1 (en) 1999-06-07 2002-07-16 Abbott Laboratories 6-O-carbamate ketolide derivatives
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
WO2001010878A1 (fr) 1999-08-06 2001-02-15 Taisho Pharmaceutical Co., Ltd. Derives d'erythromycine a
KR100336447B1 (ko) 1999-11-24 2002-05-15 민경윤 클라리스로마이신의 개선된 제조방법
JP2001261694A (ja) 2000-03-06 2001-09-26 Pfizer Prod Inc ケトライド抗生物質
BR0109194A (pt) * 2000-03-15 2003-02-11 Hanmi Pharm Ind Co Ltd Método para preparar claritromicina em cristais da forma ii
US20020115621A1 (en) 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
GB0031312D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Macrolides
CA2447600C (en) 2001-05-18 2015-10-20 Chiron Corporation Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
EP1404693A2 (en) 2001-07-03 2004-04-07 Chiron Corporation C12 modified erythromycin macrolides and ketolides having antibacterial activity
US20030176327A1 (en) 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
US20040019012A1 (en) 2002-02-22 2004-01-29 Singh Satish K. Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
EP2226316B1 (en) 2002-05-30 2016-01-13 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
AR043050A1 (es) 2002-09-26 2005-07-13 Rib X Pharmaceuticals Inc Compuestos heterociclicos bifuncionales y metodos para preparar y usar los mismos
ITMI20022292A1 (it) 2002-10-29 2004-04-30 Zambon Spa 9a-azalidi ad attivita' antiinfiammatoria.
US7601695B2 (en) * 2003-03-10 2009-10-13 Optimer Pharmaceuticals, Inc. Antibacterial agents
CA2523541A1 (en) 2003-04-25 2004-11-11 Chiron Corporation Novel ketolide derivatives
US20050014706A1 (en) 2003-07-14 2005-01-20 Kanakeshwari Falzari Method of treating tuberculosis
US7457520B2 (en) 2003-07-24 2008-11-25 Time Warner Cable, Inc. Technique for providing a virtual digital video recorder service through a communications network
US20060116336A1 (en) 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
SI1742957T1 (sl) 2004-04-28 2008-04-30 Alembic Ltd Postopek za pripravo telitromicina
JP2008508322A (ja) 2004-07-28 2008-03-21 ランバクシー ラボラトリーズ リミテッド 抗菌剤としてのケトライド誘導体
PL1836211T3 (pl) * 2004-12-21 2010-07-30 Pfizer Prod Inc Makrolidy
ATE477805T1 (de) 2005-01-14 2010-09-15 Glaxosmithkline Zagreb 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl- y-aminopropyl-azalide mit antimalaria-aktivität
WO2007039914A2 (en) 2005-10-06 2007-04-12 Alembic Limited Novel polymorphs of telithromycin
WO2007059307A2 (en) * 2005-11-15 2007-05-24 Teva Pharmaceutical Industries Ltd. Crystalline and amorphous forms of telithromycin
WO2007060627A2 (en) 2005-11-23 2007-05-31 Ranbaxy Laboratories Limited Use of macrolide derivatives for treating acne
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
CN101129383B (zh) 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
US7742562B2 (en) * 2007-06-27 2010-06-22 Accuray Incorporated Lower-torso assembly of a treatment couch useable in an X-ray environment
WO2009053259A1 (en) 2007-10-25 2009-04-30 Sandoz Ag Process for the production of telithromycin
EP2214484A4 (en) * 2007-10-25 2013-01-02 Cempra Pharmaceuticals Inc PROCESS FOR PREPARING ANTIBACTERIAL MAKROLIDE AGENTS
CN102245195B (zh) * 2008-10-24 2016-01-13 森普拉制药公司 使用含三唑的大环内酯的生物防御
AU2011224238B2 (en) 2010-03-10 2015-11-26 Cempra Pharmaceuticals, Inc. Parenteral formulations of macrolide antibiotics
EP3009442B1 (en) * 2010-03-22 2019-06-19 Cempra Pharmaceuticals, Inc. Crystalline forms of a macrolide, and uses therefor

Also Published As

Publication number Publication date
KR102006200B1 (ko) 2019-08-01
CA2793884A1 (en) 2011-09-29
RU2012144614A (ru) 2014-04-27
CN108570083A (zh) 2018-09-25
PL2550286T3 (pl) 2016-07-29
AU2011232627B2 (en) 2016-03-17
BR112012023950A2 (pt) 2016-07-05
JP6121387B2 (ja) 2017-04-26
KR20130056226A (ko) 2013-05-29
JP2017081953A (ja) 2017-05-18
JP5711352B2 (ja) 2015-04-30
US8975386B2 (en) 2015-03-10
US20130252915A1 (en) 2013-09-26
JP2020002168A (ja) 2020-01-09
KR20180101643A (ko) 2018-09-12
MX361413B (es) 2018-12-05
US20190040096A1 (en) 2019-02-07
AU2011232627A1 (en) 2012-10-18
ES2564097T3 (es) 2016-03-17
HK1177937A1 (en) 2013-08-30
EP2550286A4 (en) 2013-10-02
SI2550286T1 (sl) 2016-04-29
JP2013522367A (ja) 2013-06-13
EP3009442A1 (en) 2016-04-20
EP2550286B1 (en) 2015-12-09
MX2012010895A (es) 2013-02-15
DK2550286T3 (en) 2016-02-29
AU2016203986B2 (en) 2016-10-06
WO2011119604A1 (en) 2011-09-29
JP2015063536A (ja) 2015-04-09
RU2650883C2 (ru) 2018-04-18
MY162411A (en) 2017-06-15
US8759500B2 (en) 2014-06-24
NZ602544A (en) 2014-11-28
EP3009442B1 (en) 2019-06-19
US20130018008A1 (en) 2013-01-17
CN103080122A (zh) 2013-05-01
IL222018B (en) 2019-05-30
EP2550286A1 (en) 2013-01-30
US20160244472A1 (en) 2016-08-25
AU2016203986A1 (en) 2016-06-30
CA2793884C (en) 2019-09-10

Similar Documents

Publication Publication Date Title
HRP20160168T1 (hr) Kristalne forme makrolida i njihova uporaba
HRP20141137T1 (hr) Polimorfni oblici macrocikliäśkog inhibitora hcv
HRP20201275T1 (hr) Kristalni oblik derivata benzimidazola i postupak njegove proizvodnje
HRP20160208T4 (hr) Polimorfi dasatiniba i postupak za njihovu pripremu
HRP20201644T1 (hr) Kristalni oblik 2-butoksi-7-(4-(pirolidin-1-ilmetil)benzil)-5h-pirolo [3,2-d]pirimidin-4-amina kao agonist tlr7, postupak njegove proizvodnje i njegova uporaba
RU2015137928A (ru) Полиморфные и псевдоплиморфные формы фармацевтического соединения
CN102746258B (zh) 卡巴他赛的结晶形式及其制备方法
HRP20210507T1 (hr) Supstituirani 5-fluoro-1h-pirazolopiridini u kristalnom obliku
HRP20170187T1 (hr) Polimorfni oblici 2-(5-brom-4-(4-ciklopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio) octene kiseline i njihova upotreba
HRP20150584T1 (hr) Soli i polimorfi tetraciklinskog spoja
CN102838571B (zh) 含γ-亚基丁烯内酯穿心莲内酯衍生物、其合成方法和用途
RU2018145948A (ru) Кристалл пирролопиримидина для получения jak-ингибитора
HRP20130026T1 (hr) Kristalni oblik posakonazola
RU2014110399A (ru) Кристаллические формы вгс протеазного ингибитора
RU2009131727A (ru) Макроциклические полиморфы, композиции, содержащие такие полиморфы, и способы их применения и получения
RU2015100280A (ru) Многокомпонентные кристаллы, содержащие дазатиниб и определенные сокристаллобразователи
HRP20191525T1 (hr) Inhibitori replikacije virusa influence
TW201708245A (zh) 涎酸轉移酶抑制劑及其用途
JP2022060192A5 (enExample)
RU2019106531A (ru) Кристалл соли производного хиназолина
ITMI20131307A1 (it) Processo per la preparazione di refaximina k
HRP20201178T1 (hr) Natrijeva sol inhibitora transportera mokraćne kiseline i njen kristalni oblik
HRP20191522T1 (hr) Kristalinični oblici s-acetil-glutationa, njihove priprave i upotrebe u farmaceutskim i nutraceutskim formulacijama
RU2011143805A (ru) Кристаллы гидробромата прасугреля
CN103880904B (zh) 非达霉素晶型i及其制备方法